HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2643-2647

  Osman, Iman ^a   Scher, Howard I ^a   Morris, Michael ^a   Agus, David ^a   Drobnjak, Marija ^a   Cordon Cardo, Carlos ^a   Verbel, David ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER STAGING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

COHORT STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 0034808673     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
2. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples
3. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary
4. Genetic evolutionary staging of early non-small cell lung cancer: The P53 HER-2/NEU ras sequence
5. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro
6. Recombinant oncotoxin AR209 (anti-p185/erbB-2) diminishes human prostate cancer xenografts
7. c-erbB-2 oncoprotein expression in primary human tumors
8. Immunohistochemical detection of c-erbB2 protein in human benign and neoplastic prostate
9. P53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
10. Expression of epidermal growth factor receptor and c-erbB-2 (HER-2/neu) oncoprotein in prostatic carcinomas
11. Differential immunoreactivity of HER-2/neu oncoprotein in prostatic tissues
12. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: An immunohistochemical study
13. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma
14. Clinical states in prostate cancer
15. Prostatic adenocarcinoma following androgen deprivation therapy. The new difficulty in histologic interpretation
16. Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies
17. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-Approved Scoring System
18. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression
19. Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer
20. Evaluation of survival data and two new rank order statistics arising in its consideration
21. Nonparametric estimation from incomplete observation
22. Regression models and life tables
23. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma
24. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer
25. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
26. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia
27. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma
28. Her-2-neu expression and progression toward androgen independence in human prostate cancer
29. Cell type-dependent and -independent control of HER-2/neu translation
30. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas
31. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer
32. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer
33. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ-hybridization
34. Expression of c-erbB-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilagenous framework and prognosis
35. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
36. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications
37. Response of prostate cancer to anti-Her-2/neu antibody in androgen dependent and independent human xenograft models